These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8898645)

  • 21. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S; Miglioli M; Barbara L
    J Hepatol; 1995; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.
    Schvarcz R; Yun ZB; Sönnerborg A; Weiland O
    J Med Virol; 1995 May; 46(1):43-7. PubMed ID: 7623006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
    Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
    N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy.
    Wietzkebetaraun P; Meier V; Braun F; Ramadori G
    World J Gastroenterol; 2001 Apr; 7(2):222-7. PubMed ID: 11819764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
    Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of chronic hepatitis D with interferon alfa-2a.
    Farci P; Mandas A; Coiana A; Lai ME; Desmet V; Van Eyken P; Gibo Y; Caruso L; Scaccabarozzi S; Criscuolo D
    N Engl J Med; 1994 Jan; 330(2):88-94. PubMed ID: 8259188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
    McHutchison JG; Lawitz EJ; Shiffman ML; Muir AJ; Galler GW; McCone J; Nyberg LM; Lee WM; Ghalib RH; Schiff ER; Galati JS; Bacon BR; Davis MN; Mukhopadhyay P; Koury K; Noviello S; Pedicone LD; Brass CA; Albrecht JK; Sulkowski MS;
    N Engl J Med; 2009 Aug; 361(6):580-93. PubMed ID: 19625712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
    Chapman BA; Stace NH; Edgar CL; Bartlett SE; Frampton CM; Scahill SL; Jennings LC
    N Z Med J; 2001 Mar; 114(1128):103-4. PubMed ID: 11346153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
    Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
    Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
    Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
    Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
    Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
    Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.
    Fried MW; Peter J; Hoots K; Gaglio PJ; Talbut D; Davis PC; Key NS; White GC; Lindblad L; Rickles FR; Abshire TC
    Hepatology; 2002 Oct; 36(4 Pt 1):967-72. PubMed ID: 12297845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
    Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
    Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.